The use of serum eosinophil cationic protein (ECP) in the management of steroid therapy in chronic asthma

Wever, A.M.J.; Wever-Hess, J.; Hermans, J.

doi:10.1111/j.1365-2222.1997.tb00740.x

Cited by 30 publications

(11 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lower Gecp in our studied group was probably the result of the heterogeneity of the given group related to the severity and exacerbation of the disease. Geometric mean of ECP in our studied group (3.056 mg/L) was compatible with the control values (4.4 mg/L) of the producer of the serum ECP testing commercial kit, as well as with the reference data (5,9). Ahlstedt et al (10) reported that Gecp=3'5 mg/L in healthy persons, while somewhat higher values were found in children: 6.5 mg/L (11).…”

Section: Discussionsupporting

confidence: 88%

“…ECP can be measured in body fluids and quantitated in serum as well, which is an accessible medium in clinical practice. Results from previous clinical evaluation of serum ECP in chronic asthma suggested that serum ECP is a sensitive marker of inflammatory airflow obstruction and that elevated levels denote patients at risk from inflammatory exacerbations, independent of atopic status, indicating the need to intensify treatment with corticosteroids (5).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The serum eosinophil cationic protein concentration in patients with bronchial asthma and its correlation with severity and exacerbation of the disease

Kovacevic

Perić-Popadić

et al. 2003

Jugoslav Med Biohem

View full text Add to dashboard Cite

Activated eosinophilic leukocyte in asthma secrete numerous mediators, among which is ECP as well. The object of our study was to measure the serum ECP concentrations in 46 asthmatic patients with exacerabating and stable asthma, and to correlate the serum ECP concentrations with severity and exacerbation of the disease. Geometric mean of ECP in serum (Gecp) in our group of patients was 7.5 mcg/l, while it was 3.05 mcg/l in the 15 healthy subjects (controls). Highly significant correlation of serum ECP concentrations with the activity of the disease (R=0.897) and the severity of clinical picture (R=0.79) was found. The patients with stable asthma had significant correlation of ECP and the severity of disease (R=0.6). The patients with exacerbating asthma have significantly higher serum ECP concentrations than the patients with stable asthma. Serum ECP concentrations in patients with exacerbating asthma correlate with the severity of the disease.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Introductionmentioning

confidence: 99%

The serum eosinophil cationic protein concentration in patients with bronchial asthma and its correlation with severity and exacerbation of the disease

Kovacevic

Perić-Popadić

et al. 2003

Jugoslav Med Biohem

View full text Add to dashboard Cite

show abstract

“…Clinical investigations have reported that eosinophils are increased in the sputum and bronchial biopsies of patients with AECOPD (31,32). Increased levels of ECP in serum (24,33), bronchoalveolar lavage fluid (34) and induced sputum (35) have been observed in patients with AECOPD. Hospers et al (20) proposed that peripheral blood eosinophilia may also lead to a higher mortality rate for patients with AECOPD.…”

Section: Discussionmentioning

confidence: 99%

Eosinophilic biomarkers for detection of acute exacerbation of chronic obstructive pulmonary disease with or without pulmonary embolism

Yang

Lü

Shu

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Eosinophilia has been implicated in the pathophysiology of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). However, the role of eosinophil activation in the development of AECOPD remains unclear. In the present study, the reliability of plasma levels of eosinophil activation markers, including eosinophil cationic protein (ECP), major basic protein (MBP), eosinophil-derived neurotoxin (EDN) and eosinophil peroxidase (EPX), were measured and used as diagnostic biomarkers of AECOPD with or without pulmonary embolism (PE). A total of 47 patients with AECOPD, 30 patients with AECOPD/PE and 35 healthy adults were enrolled in the present study. Plasma levels of ECP, EDN, EPX and MBP were measured using commercial ELISA kits. The mean concentrations of plasma ECP, EDN, EPX and MBP in the patients with AECOPD was significantly 2.87-, 3.06-, 1.60-and 1.92-fold higher, respectively, compared with the control group (P<0.05). Similar results were obtained in patients with AECOPD/PE, for whom plasma levels of ECP, EDN, EPX and MBP were significantly 2.06-, 2.21-, 1.42-and 2.42-fold higher, respectively, compared with the controls (P<0.05). No significant differences were observed in the levels of these proteins between patients with AECOPD or AECOPD/PE. Among the four potential markers, ECP was determined to be the optimal marker for distinguishing patients with AECOPD or AECOPD/PE from the controls. No significant correlation was observed between marker concentrations and gender, age or disease severity. The results of the present study may have clinical applications in the diagnosis of AECOPD using these novel biomarkers.

show abstract

“…Several studies have demonstrated that serum levels of ECP are elevated in patients with asthma [33, 34, 35, 36, 37, 38]with respect to patients with rhinitis [18, 19, 20, 21]. Despite having been used for a number of years, the exact role for serum ECP measurements in asthma is still a matter of debate.…”

Section: Discussionmentioning

confidence: 99%

Measurement of Inflammatory Mediators of Eosinophils and Lymphocytes in Blood in Acute Asthma: Serum Levels of ECP Influence the Bronchodilator Response

Lorenzo¹,

Pacor

Morici³

et al. 2002

Int Arch Allergy Immunol

View full text Add to dashboard Cite

The aim of this study was to assess the relevance of immunoinflammatory markers on the response to short acting β₂-agonist in acute asthma exacerbation. Thus, we measured serum eosinophil cationic protein (ECP) levels and sIL-2R at acute exacerbation in 52 adult patients with atopic asthma, and assessed forced expiratory volume in 1 s (FEV₁) before and after the administration of aerosolized salbutamol. After a cumulative dose of salbutamol causing a 10% improvement in FEV₁ from baseline [CD10, i.e. cumulative doses of salbutamol (800 µg) causing an improvement in FEV₁ from baseline to 10%] the patients were divided into two groups: group A with CD <10 and group B with CD >10. The bronchodilator response, as defined by a ΔFEV₁ (percentage of predictive value of FEV₁) of ≧10 predictive value, was shown by 40% of the patients. After 200, 400 and 800 µg of salbutamol, significant differences of FEV₁ with respect to baseline values were, respectively, p = 0.049, 0.0039 and 0.0014. In contrast, no significant difference of the means of FEV₁ between the doses of salbutamol was observed. Significant differences of ΔFEV₁ between 200 and 400 µg (p = 0.0002) and between 200 and 800 µg (p < 0.0001) were observed, but not between 400 and 800 µg of salbutamol. There were significant correlations between baseline values of predictive FEV₁ and serum ECP levels (rho = –0.60, p < 0.0001) and sIL-2R levels (rho = –0.35, p = 0.01) respectively. Besides, a correlation between ΔFEV₁ and serum ECP levels (rho = –0.53, p < 0.0001) was observed, whereas no correlation was found between ΔFEV₁ and sIL-2R. By analyzing differences between the two groups (A and B) for serum ECP levels, sIL-2R and blood eosinophil count, a significant difference was found for serum ECP levels. We conclude that subjects with acute exacerbation of asthma show high serum levels of ECP and sIL-2R and, more interestingly, that the response to brochodilator was higher in patients with lower serum ECP levels.

show abstract

The use of serum eosinophil cationic protein (ECP) in the management of steroid therapy in chronic asthma

Abstract: From this observational study it is concluded that adjusting steroid therapy guided by serum ECP-level may be helpful in tailoring asthma treatment.

Cited by 30 publications

References 39 publications

The serum eosinophil cationic protein concentration in patients with bronchial asthma and its correlation with severity and exacerbation of the disease

The serum eosinophil cationic protein concentration in patients with bronchial asthma and its correlation with severity and exacerbation of the disease

Eosinophilic biomarkers for detection of acute exacerbation of chronic obstructive pulmonary disease with or without pulmonary embolism

Measurement of Inflammatory Mediators of Eosinophils and Lymphocytes in Blood in Acute Asthma: Serum Levels of ECP Influence the Bronchodilator Response

Contact Info

Product

Resources

About